{
    "clinical_study": {
        "@rank": "89033", 
        "acronym": "XP China SAS", 
        "arm_group": {
            "arm_group_label": "XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS)", 
            "description": "Subjects receiving XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS)"
        }, 
        "brief_summary": {
            "textblock": "Abbott Vascular (AV) obtained marketing approval for the XIENCE PRIME Everolimus Eluting\n      Coronary Stent System (XIENCE PRIME EECSS) in China from the China Food and Drug\n      Administration (CFDA) on August 10th, 2011.\n\n      This prospective, observational, open-label, multi-center, single-arm, post-approval study\n      is designed to evaluate the continued safety and effectiveness of the XIENCE PRIME EECSS in\n      a cohort of real-world patients receiving the XIENCE PRIME EECSS during commercial use in\n      real-world settings in China.\n\n      This study has no primary outcome measure. All observations are of equal weight."
        }, 
        "brief_title": "XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS) China Single-Arm Study", 
        "completion_date": {
            "#text": "July 2019", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Angioplasty", 
            "Cardiovascular Disease", 
            "Chronic Coronary Occlusion", 
            "Coronary Artery Bypass Graft (CABG)", 
            "Coronary Artery Disease", 
            "Coronary Heart Disease", 
            "Coronary Restenosis", 
            "Myocardial Infarction", 
            "Myocardial Ischemia", 
            "Stent Thrombosis", 
            "Vascular Disease"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Cardiovascular Diseases", 
                "Coronary Artery Disease", 
                "Myocardial Ischemia", 
                "Coronary Disease", 
                "Heart Diseases", 
                "Infarction", 
                "Ischemia", 
                "Myocardial Infarction", 
                "Thrombosis", 
                "Vascular Diseases", 
                "Coronary Occlusion", 
                "Coronary Restenosis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  The patient must be at least 18 years of age at the time of signing the informed\n             consent.\n\n          -  The patient or his/her legally-authorized representative signs the EC-approved\n             Informed Consent Form (ICF).\n\n          -  Only XIENCE PRIME stent(s) is (are) implanted during the index procedure.\n\n        Exclusion Criteria:\n\n          -  No other exclusion criteria are specified for this study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Cohort of real-world patients receiving the XIENCE PRIME EECSS during commercial use in\n        realworld settings in China."
            }
        }, 
        "enrollment": {
            "#text": "2000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 1, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01894152", 
            "org_study_id": "12-396"
        }, 
        "intervention": {
            "arm_group_label": "XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS)", 
            "description": "Subjects receiving XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS)", 
            "intervention_name": "XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS)", 
            "intervention_type": "Device"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Everolimus", 
                "Sirolimus"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "XIENCE PRIME EECSS", 
            "XIENCE V EECSS", 
            "XIENCE PRIME", 
            "SPIRIT PRIME", 
            "XIENCE PRIME SV (Small Vessel)", 
            "XIENCE PRIME LL (Long Lesion)", 
            "Coronary Artery Disease", 
            "Coronary Artery Bypass Graft (CABG)", 
            "Coronary Heart Disease", 
            "Cardiovascular Disease", 
            "Myocardial Infarction", 
            "Stent Thrombosis"
        ], 
        "lastchanged_date": "January 6, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Santa Clara", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "95054"
                }, 
                "name": "Abbott Vascular"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "1", 
        "official_title": "Evaluate the Continued Safety and Effectiveness of the XIENCE PRIME EECSS in a Cohort of Real-world Patients Receiving the XIENCE PRIME EECSS During Commercial Use.", 
        "overall_contact": {
            "email": "roy.leong@abbott.com", 
            "last_name": "Roy Leong", 
            "phone": "+65 62773202"
        }, 
        "overall_official": [
            {
                "affiliation": "Fudan University", 
                "last_name": "Junbo Ge, MB, MSc, MD, FACC, FESC, FSCAI", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Chinese PLA General Hospital", 
                "last_name": "Yundai Chen, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Anzhen Hospital", 
                "last_name": "Fang Chen, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Composite rate of cardiac death and all myocardial infarction (MI) (Q-wave and non-Qwave)", 
                "safety_issue": "Yes", 
                "time_frame": "1 year"
            }, 
            {
                "measure": "Composite rate of cardiac death and all myocardial infarction (MI) (Q-wave and non-Qwave)", 
                "safety_issue": "Yes", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "Composite rate of cardiac death and all myocardial infarction (MI) (Q-wave and non-Qwave)", 
                "safety_issue": "Yes", 
                "time_frame": "3 years"
            }, 
            {
                "measure": "Composite rate of cardiac death and all myocardial infarction (MI) (Q-wave and non-Qwave)", 
                "safety_issue": "Yes", 
                "time_frame": "4  years"
            }, 
            {
                "measure": "Composite rate of cardiac death and all myocardial infarction (MI) (Q-wave and non-Qwave)", 
                "safety_issue": "Yes", 
                "time_frame": "5 years"
            }, 
            {
                "measure": "Composite rate of all death and all myocardial infarction (MI) (Q-wave and non-Q-wave)", 
                "safety_issue": "Yes", 
                "time_frame": "1 year"
            }, 
            {
                "measure": "Composite rate of all death and all myocardial infarction (MI) (Q-wave and non-Q-wave)", 
                "safety_issue": "Yes", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "Composite rate of all death and all myocardial infarction (MI) (Q-wave and non-Q-wave)", 
                "safety_issue": "Yes", 
                "time_frame": "3 years"
            }, 
            {
                "measure": "Composite rate of all death and all myocardial infarction (MI) (Q-wave and non-Q-wave)", 
                "safety_issue": "Yes", 
                "time_frame": "4 years"
            }, 
            {
                "measure": "Composite rate of all death and all myocardial infarction (MI) (Q-wave and non-Q-wave)", 
                "safety_issue": "Yes", 
                "time_frame": "5 years"
            }, 
            {
                "measure": "Target lesion failure (TLF): the composite rate of cardiac death, target vessel MI (TVMI), and ischemia-driven target lesion revascularization (ID-TLR)", 
                "safety_issue": "Yes", 
                "time_frame": "1 year"
            }, 
            {
                "measure": "Target lesion failure (TLF): the composite rate of cardiac death, target vessel MI (TVMI), and ischemia-driven target lesion revascularization (ID-TLR)", 
                "safety_issue": "Yes", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "Target lesion failure (TLF): the composite rate of cardiac death, target vessel MI (TVMI), and ischemia-driven target lesion revascularization (ID-TLR)", 
                "safety_issue": "Yes", 
                "time_frame": "3 years"
            }, 
            {
                "measure": "Target lesion failure (TLF): the composite rate of cardiac death, target vessel MI (TVMI), and ischemia-driven target lesion revascularization (ID-TLR)", 
                "safety_issue": "Yes", 
                "time_frame": "4 years"
            }, 
            {
                "measure": "Target lesion failure (TLF): the composite rate of cardiac death, target vessel MI (TVMI), and ischemia-driven target lesion revascularization (ID-TLR)", 
                "safety_issue": "Yes", 
                "time_frame": "5 years"
            }, 
            {
                "measure": "Target vessel failure (TVF): the composite rate of cardiac death, all MI, and ischemiadriven target vessel revascularization (ID-TVR)", 
                "safety_issue": "Yes", 
                "time_frame": "1 year"
            }, 
            {
                "measure": "Target vessel failure (TVF): the composite rate of cardiac death, all MI, and ischemiadriven target vessel revascularization (ID-TVR)", 
                "safety_issue": "Yes", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "Target vessel failure (TVF): the composite rate of cardiac death, all MI, and ischemiadriven target vessel revascularization (ID-TVR)", 
                "safety_issue": "Yes", 
                "time_frame": "3 years"
            }, 
            {
                "measure": "Target vessel failure (TVF): the composite rate of cardiac death, all MI, and ischemiadriven target vessel revascularization (ID-TVR)", 
                "safety_issue": "Yes", 
                "time_frame": "4 years"
            }, 
            {
                "measure": "Target vessel failure (TVF): the composite rate of cardiac death, all MI, and ischemiadriven target vessel revascularization (ID-TVR)", 
                "safety_issue": "Yes", 
                "time_frame": "5 years"
            }, 
            {
                "measure": "Stent thrombosis (definite and probable, per Academic Research Consortium[ARC] definition)", 
                "safety_issue": "Yes", 
                "time_frame": "1 year"
            }, 
            {
                "measure": "Stent thrombosis (definite and probable, per Academic Research Consortium[ARC] definition)", 
                "safety_issue": "Yes", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "Stent thrombosis (definite and probable, per Academic Research Consortium[ARC] definition)", 
                "safety_issue": "Yes", 
                "time_frame": "3 years"
            }, 
            {
                "measure": "Stent thrombosis (definite and probable, per Academic Research Consortium[ARC] definition)", 
                "safety_issue": "Yes", 
                "time_frame": "4 years"
            }, 
            {
                "measure": "Stent thrombosis (definite and probable, per Academic Research Consortium[ARC] definition)", 
                "safety_issue": "Yes", 
                "time_frame": "5 years"
            }, 
            {
                "measure": "Death (cardiac, vascular, and non-cardiovascular)", 
                "safety_issue": "Yes", 
                "time_frame": "1 year"
            }, 
            {
                "measure": "Death (cardiac, vascular, and non-cardiovascular)", 
                "safety_issue": "Yes", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "Death (cardiac, vascular, and non-cardiovascular)", 
                "safety_issue": "Yes", 
                "time_frame": "3 years"
            }, 
            {
                "measure": "Death (cardiac, vascular, and non-cardiovascular)", 
                "safety_issue": "Yes", 
                "time_frame": "4 years"
            }, 
            {
                "measure": "Death (cardiac, vascular, and non-cardiovascular)", 
                "safety_issue": "Yes", 
                "time_frame": "5 years"
            }, 
            {
                "measure": "All MI (including Q-wave and non-Q-wave)", 
                "safety_issue": "Yes", 
                "time_frame": "1 year"
            }, 
            {
                "measure": "All MI (including Q-wave and non-Q-wave)", 
                "safety_issue": "Yes", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "All MI (including Q-wave and non-Q-wave)", 
                "safety_issue": "Yes", 
                "time_frame": "3 years"
            }, 
            {
                "measure": "All MI (including Q-wave and non-Q-wave)", 
                "safety_issue": "Yes", 
                "time_frame": "4 years"
            }, 
            {
                "measure": "All MI (including Q-wave and non-Q-wave)", 
                "safety_issue": "Yes", 
                "time_frame": "5 years"
            }, 
            {
                "measure": "Revascularization (target lesion, target vessel, and non-target vessel) (PCI and Coronary Artery Bypass Graft [CABG])", 
                "safety_issue": "Yes", 
                "time_frame": "1 year"
            }, 
            {
                "measure": "Revascularization (target lesion, target vessel, and non-target vessel) (PCI and Coronary Artery Bypass Graft [CABG])", 
                "safety_issue": "Yes", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "Revascularization (target lesion, target vessel, and non-target vessel) (PCI and Coronary Artery Bypass Graft [CABG])", 
                "safety_issue": "Yes", 
                "time_frame": "3 years"
            }, 
            {
                "measure": "Revascularization (target lesion, target vessel, and non-target vessel) (PCI and Coronary Artery Bypass Graft [CABG])", 
                "safety_issue": "Yes", 
                "time_frame": "4 years"
            }, 
            {
                "measure": "Revascularization (target lesion, target vessel, and non-target vessel) (PCI and Coronary Artery Bypass Graft [CABG])", 
                "safety_issue": "Yes", 
                "time_frame": "5 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01894152"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Abbott Vascular", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Abbott Vascular", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "January 2014"
    }
}